Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.
Market Cap
$286.88M
P/E Ratio
-17.42
1Y Stock Return
42.61%
1Y Revenue Growth
-9.91%
Dividend Yield
0.00%
Price to Book
0.5
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
ORKA | 39.82% | $780.47M | +82.82% | 0.00% |
CODX | 31.70% | $34.16M | -25.17% | 0.00% |
PAHC | 31.33% | $961.96M | +131.93% | 2.04% |
SUNS | 31.15% | $105.89M | +35.31% | 1.37% |
WOW | 31.13% | $434.90M | +18.48% | 0.00% |
SMAR | 30.74% | $7.79B | +36.62% | 0.00% |
ALDX | 28.23% | $294.18M | +102.46% | 0.00% |
NXDT | 28.18% | $218.01M | -37.42% | 11.58% |
STHO | 28.10% | $150.51M | -5.99% | 0.00% |
HALO | 27.66% | $5.70B | +15.25% | 0.00% |
CLDX | 26.59% | $1.66B | -10.82% | 0.00% |
DAWN | 26.56% | $1.36B | +13.42% | 0.00% |
RC | 26.46% | $1.22B | -27.41% | 15.95% |
GRAL | 26.46% | $459.22M | -13.00% | 0.00% |
CUZ | 26.43% | $4.89B | +57.48% | 4.17% |
AXSM | 26.42% | $4.63B | +61.30% | 0.00% |
ILMN | 26.41% | $21.41B | +44.38% | 0.00% |
RARE | 26.39% | $4.17B | +16.19% | 0.00% |
GOLF | 26.31% | $4.21B | +20.68% | 1.22% |
CNH | 26.26% | $13.83B | +9.71% | 4.23% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
LIVN | 0.01% | $2.79B | +18.18% | 0.00% |
SPR | 0.03% | $3.72B | +23.27% | 0.00% |
CME | 0.03% | $82.76B | +9.21% | 1.98% |
BRFS | -0.04% | $6.90B | +48.76% | 0.00% |
OMCL | -0.04% | $1.96B | +30.61% | 0.00% |
NGL | -0.07% | $572.94M | +5.60% | 0.00% |
CMG | -0.08% | $80.02B | +33.62% | 0.00% |
TLPH | 0.11% | $11.41M | +9.85% | 0.00% |
KOS | -0.14% | $1.85B | -42.25% | 0.00% |
TPB | 0.17% | $1.08B | +167.44% | 0.45% |
DLNG | -0.19% | $161.93M | +73.23% | 0.00% |
ZTO | -0.21% | $12.58B | -4.71% | 4.73% |
KB | 0.22% | $24.84B | +59.60% | 4.17% |
LICY | 0.23% | $53.41M | -60.56% | 0.00% |
GHI | -0.24% | $272.26M | -27.60% | 12.75% |
AB | 0.24% | $4.14B | +29.43% | 8.13% |
NTZ | 0.26% | $47.64M | -30.94% | 0.00% |
SNCR | 0.26% | $97.34M | +78.17% | 0.00% |
CPB | -0.29% | $12.96B | +7.08% | 3.40% |
KRRO | -0.30% | $436.84M | +20.68% | 0.00% |
Yahoo
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the following upcoming investor conferences in November 2024:
Yahoo
Vanda Pharmaceuticals Inc (VNDA) reports a 23% revenue increase in Q3 2024, driven by Fanapt sales, despite a net loss and increased operating expenses.
Yahoo
WASHINGTON (AP) — Vanda Pharmaceuticals Inc. VNDA) on Wednesday reported a loss of $5.3 million in its third quarter. The Washington-based company said it had a loss of 9 cents per share.
Yahoo
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the third quarter ended September 30, 2024.
SeekingAlpha
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ETCompany ParticipantsKevin Moran â Chief Financial...
Finnhub
Vanda Pharmaceuticals Reports Third Quarter 2024 Financial Results •Revenues for Q3 2024 were $47.7 million, an increase of 23% compared to Q3 2023 •Financial...
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.
Current Value
$4.901 Year Return
Current Value
$4.901 Year Return
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
QTTB | -11.13% | $354.34M | +188.64% | 0.00% |
TCTM | -10.90% | $8.10M | -42.99% | 0.00% |
HUSA | -10.49% | $16.69M | -11.56% | 0.00% |
CYD | -9.37% | $364.46M | -2.94% | 4.26% |
PRPO | -9.13% | $9.10M | -13.65% | 0.00% |
NOMD | -9.03% | $2.74B | +4.53% | 2.67% |
OCX | -8.95% | $42.93M | -36.09% | 0.00% |
WHLM | -8.50% | $17.64M | -29.34% | 0.00% |
NEUE | -8.44% | $40.93M | -34.13% | 0.00% |
IMNN | -7.51% | $10.02M | -22.89% | 0.00% |
SOLV | -7.17% | $11.58B | -16.19% | 0.00% |
UFI | -6.92% | $102.66M | -11.22% | 0.00% |
PRPH | -6.63% | $18.14M | -82.61% | 0.00% |
LPTH | -6.63% | $62.27M | +33.05% | 0.00% |
VERX | -6.51% | $7.99B | +89.70% | 0.00% |
TRV | -6.50% | $58.86B | +48.10% | 1.59% |
RAMP | -6.40% | $1.86B | -16.17% | 0.00% |
MFG | -6.39% | $63.12B | +43.52% | 1.44% |
DT | -6.00% | $15.40B | -1.30% | 0.00% |
NVDA | -5.48% | $3.61T | +194.35% | 0.07% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -18.27% | $388.04M | 1.43% |
VIXY | -16.04% | $195.31M | 0.85% |
KRBN | -14.09% | $242.47M | 0.85% |
CTA | -13.88% | $350.27M | 0.78% |
UUP | -13.59% | $309.25M | 0.77% |
XBIL | -10.44% | $637.70M | 0.15% |
USDU | -10.20% | $201.97M | 0.5% |
KMLM | -9.82% | $353.87M | 0.9% |
TPMN | -9.56% | $40.60M | 0.65% |
DBE | -9.00% | $50.13M | 0.77% |
WEAT | -7.92% | $120.27M | 0.28% |
DBO | -7.74% | $217.57M | 0.77% |
SGOV | -7.67% | $27.53B | 0.09% |
CSHI | -7.52% | $482.85M | 0.38% |
EQLS | -7.19% | $76.08M | 1% |
DBMF | -7.06% | $1.02B | 0.85% |
UNG | -6.85% | $908.80M | 1.06% |
CANE | -6.85% | $17.72M | 0.29% |
AGZD | -6.79% | $142.76M | 0.23% |
FBY | -5.66% | $127.69M | 0.99% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
PREF | 0.05% | $999.92M | 0.55% |
FLJH | 0.15% | $74.69M | 0.09% |
DXJ | -0.16% | $3.71B | 0.48% |
CLOI | 0.20% | $715.40M | 0.4% |
JBBB | -0.25% | $1.26B | 0.49% |
HEWJ | 0.31% | $347.32M | 0.5% |
DBC | 0.33% | $1.39B | 0.87% |
PDBC | -0.49% | $4.40B | 0.59% |
XHLF | 0.78% | $874.27M | 0.03% |
COMT | -0.81% | $829.06M | 0.48% |
DBJP | -0.97% | $399.93M | 0.45% |
FLBL | 1.28% | $645.58M | 0.45% |
GSG | -1.35% | $914.42M | 0.75% |
DUSB | -1.35% | $797.63M | 0.15% |
SEIX | 1.53% | $268.81M | 0.62% |
FMF | -1.56% | $244.61M | 0.95% |
SHV | -1.60% | $18.13B | 0.15% |
MINT | -1.83% | $11.62B | 0.35% |
FLRN | -1.97% | $2.33B | 0.15% |
THTA | 2.39% | $32.20M | 0.49% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
RSPA | 42.05% | $273.87M | 0% |
PBE | 31.84% | $258.53M | 0.58% |
IHE | 30.86% | $596.23M | 0.39% |
EFAA | 30.58% | $117.38M | 0% |
XPH | 29.94% | $157.87M | 0.35% |
PBW | 29.72% | $301.18M | 0.65% |
IJJ | 29.63% | $8.03B | 0.18% |
DFSV | 29.57% | $4.16B | 0.31% |
FHLC | 29.39% | $2.73B | 0.084% |
EES | 29.30% | $668.71M | 0.38% |
IWC | 29.29% | $933.99M | 0.6% |
PTH | 29.21% | $143.31M | 0.6% |
RWJ | 29.16% | $1.75B | 0.39% |
MDIV | 29.10% | $451.99M | 0.68% |
MTBA | 29.09% | $1.56B | 0.15% |
IBHG | 28.99% | $175.24M | 0.35% |
ACES | 28.77% | $124.79M | 0.55% |
VHT | 28.72% | $17.06B | 0.1% |
YYY | 28.67% | $538.03M | 4.6% |
FMAT | 28.67% | $556.09M | 0.084% |